Eurofins Scientific Past Earnings Performance
Past criteria checks 1/6
Eurofins Scientific has been growing earnings at an average annual rate of 8.2%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 8.8% per year. Eurofins Scientific's return on equity is 7.1%, and it has net margins of 4.8%.
Key information
8.2%
Earnings growth rate
7.2%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 8.8% |
| Return on equity | 7.1% |
| Net Margin | 4.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Eurofins Scientific makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 6,724 | 326 | 133 | 0 |
| 31 Mar 24 | 6,619 | 291 | 134 | 0 |
| 31 Dec 23 | 6,515 | 257 | 136 | 0 |
| 30 Sep 23 | 6,512 | 335 | 132 | 0 |
| 30 Jun 23 | 6,510 | 414 | 128 | 0 |
| 31 Mar 23 | 6,611 | 497 | 128 | 0 |
| 31 Dec 22 | 6,712 | 581 | 128 | 0 |
| 30 Sep 22 | 6,785 | 612 | 123 | 0 |
| 30 Jun 22 | 6,857 | 643 | 117 | 0 |
| 31 Mar 22 | 6,787 | 696 | 116 | 0 |
| 31 Dec 21 | 6,718 | 749 | 115 | 0 |
| 30 Sep 21 | 6,553 | 786 | 117 | 0 |
| 30 Jun 21 | 6,388 | 824 | 118 | 0 |
| 31 Mar 21 | 5,913 | 665 | 119 | 0 |
| 31 Dec 20 | 5,439 | 505 | 119 | 0 |
| 30 Sep 20 | 5,079 | 347 | 120 | 0 |
| 30 Jun 20 | 4,719 | 190 | 120 | 0 |
| 31 Mar 20 | 4,641 | 168 | 119 | 0 |
| 31 Dec 19 | 4,563 | 146 | 117 | 0 |
| 30 Sep 19 | 4,384 | 144 | 111 | 0 |
| 30 Jun 19 | 4,205 | 143 | 106 | 0 |
| 31 Mar 19 | 3,993 | 159 | 98 | 0 |
| 31 Dec 18 | 3,781 | 175 | 90 | 0 |
| 30 Sep 18 | 3,549 | 182 | 82 | 0 |
| 30 Jun 18 | 3,318 | 190 | 75 | 0 |
| 31 Mar 18 | 3,145 | 185 | 62 | 0 |
| 31 Dec 17 | 2,971 | 179 | 48 | 0 |
| 30 Sep 17 | 2,848 | 166 | 42 | 0 |
| 30 Jun 17 | 2,725 | 152 | 35 | 0 |
| 31 Mar 17 | 2,631 | 145 | 37 | 0 |
| 31 Dec 16 | 2,537 | 138 | 38 | 0 |
| 30 Sep 16 | 2,427 | 104 | 35 | 0 |
| 30 Jun 16 | 2,317 | 69 | 32 | 0 |
| 31 Mar 16 | 2,133 | 63 | 31 | 0 |
| 31 Dec 15 | 1,950 | 56 | 30 | 0 |
| 30 Sep 15 | 1,779 | 71 | 27 | 0 |
| 30 Jun 15 | 1,609 | 86 | 24 | 0 |
| 31 Mar 15 | 1,509 | 82 | 20 | 0 |
| 31 Dec 14 | 1,410 | 78 | 15 | 0 |
| 30 Sep 14 | 1,355 | 66 | 17 | 0 |
| 30 Jun 14 | 1,299 | 53 | 19 | 0 |
| 31 Mar 14 | 1,262 | 53 | 15 | 0 |
| 31 Dec 13 | 1,226 | 53 | 12 | 0 |
Quality Earnings: ESF0 has a large one-off loss of €184.8M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: ESF0's current net profit margins (4.8%) are lower than last year (6.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ESF0's earnings have grown by 8.2% per year over the past 5 years.
Accelerating Growth: ESF0's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ESF0 had negative earnings growth (-21.3%) over the past year, making it difficult to compare to the Life Sciences industry average (-0.7%).
Return on Equity
High ROE: ESF0's Return on Equity (7.1%) is considered low.